| Primary |
| Product Used For Unknown Indication |
36.1% |
| Drug Use For Unknown Indication |
13.4% |
| Premedication |
8.4% |
| Off Label Use |
8.2% |
| Primary Immunodeficiency Syndrome |
6.9% |
| Immunodeficiency Common Variable |
5.1% |
| Hypogammaglobulinaemia |
3.4% |
| Hypertension |
2.2% |
| Asthma |
2.0% |
| Immunodeficiency |
1.9% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
1.9% |
| Myasthenia Gravis |
1.8% |
| Dementia Alzheimer's Type |
1.5% |
| Multiple Sclerosis |
1.2% |
| Pain |
1.2% |
| Prophylaxis |
1.1% |
| Idiopathic Thrombocytopenic Purpura |
1.0% |
| Guillain-barre Syndrome |
0.9% |
| Secondary Immunodeficiency |
0.9% |
| Supplementation Therapy |
0.8% |
|
| Infection |
13.4% |
| Death |
11.6% |
| Urticaria |
9.1% |
| Pyrexia |
8.3% |
| Vomiting |
7.5% |
| Haemolysis |
5.1% |
| Tremor |
4.2% |
| Chills |
4.1% |
| Drug Ineffective |
3.8% |
| Tachycardia |
3.8% |
| Drug Intolerance |
3.6% |
| Hypersensitivity |
3.5% |
| Meningitis Aseptic |
3.3% |
| Headache |
3.1% |
| Nausea |
3.0% |
| Pneumonia |
3.0% |
| Rash |
2.9% |
| Sinusitis |
2.5% |
| Hepatitis B |
2.0% |
| Pulmonary Embolism |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
24.7% |
| Off Label Use |
17.5% |
| Drug Use For Unknown Indication |
11.7% |
| Premedication |
8.8% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
4.5% |
| Immunodeficiency Common Variable |
3.8% |
| Demyelinating Polyneuropathy |
3.5% |
| Multiple Sclerosis |
2.8% |
| Asthma |
2.6% |
| Wegener's Granulomatosis |
2.6% |
| Myasthenia Gravis |
2.5% |
| Primary Immunodeficiency Syndrome |
2.4% |
| Hypogammaglobulinaemia |
2.3% |
| Prophylaxis |
2.1% |
| Drug Exposure During Pregnancy |
1.8% |
| Rash Erythematous |
1.4% |
| Secondary Immunodeficiency |
1.4% |
| Pyrexia |
1.3% |
| Chronic Lymphocytic Leukaemia |
1.2% |
| Hypertension |
1.2% |
|
| Hepatitis B Antibody Positive |
20.3% |
| Urticaria |
7.2% |
| Anti-hbs Antibody Positive |
7.0% |
| Pyrexia |
6.5% |
| Vomiting |
6.5% |
| Sleep Disorder |
6.1% |
| Hepatitis B |
5.9% |
| Pulmonary Embolism |
5.2% |
| Anti-erythrocyte Antibody Positive |
5.1% |
| Haemolysis |
4.6% |
| Haemolytic Transfusion Reaction |
4.0% |
| Hepatic Enzyme Increased |
4.0% |
| Tremor |
2.8% |
| Sensation Of Heaviness |
2.6% |
| Pneumonia |
2.3% |
| Pruritus |
2.1% |
| Chills |
2.1% |
| Tachycardia |
2.1% |
| Drug Ineffective |
1.9% |
| Off Label Use |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.3% |
| Blood Immunoglobulin A Decreased |
16.7% |
| Bronchitis |
16.7% |
| Idiopathic Thrombocytopenic Purpura |
16.7% |
| Immunodeficiency Common Variable |
16.7% |
|
| Fibrosis |
20.0% |
| Maternal Exposure During Pregnancy |
20.0% |
| Meningitis Aseptic |
20.0% |
| Rash Generalised |
20.0% |
| Vomiting |
20.0% |
|
